Given that CAMK2B promotes the progression of glioma through the activation of the MAPK kinase signaling pathway, indirectly targeting CAMK2B using MAPK kinase inhibitors is a potential therapeutic strategy for glioma. Here, CAMK2B is linked to central nervous system cancer.